Astellas Pharma Inc (4503.T)
5,490JPY
2 Jul 2013
¥60 (+1.10%)
¥5,100
¥5,560
¥5,570
¥5,440
1,236,600
2,253,098
¥6,010
¥3,435
4503.T
About
Overall
| Beta: | 0.60 |
| Market Cap (Mil.): | ¥2,481,318.00 |
| Shares Outstanding (Mil.): | 456.96 |
| Dividend: | 65.00 |
| Yield (%): | 2.39 |
Financials
| 4503.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 30.26 | 32.01 | 32.18 |
| EPS (TTM): | 179.42 | -- | -- |
| ROI: | 7.47 | 19.61 | 18.91 |
| ROE: | 7.97 | 20.45 | 19.87 |
Deals of the day -- mergers and acquisitions
(Updates Kabel Deutschland; Adds Siemens, PPR, Dell, Astellas Pharma, Nokia, Lekoil, Nordea, Chevron)
Exclusive: Japan's Astellas looks to sell dermatology assets - sources
NEW YORK - Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
Amgen to make move into Japan, takes on Astellas as partner
- Amgen Inc, the world's largest biotechnology company, said it entered into a long-term collaboration with Astellas Pharma Inc and will form a joint venture with the Japanese drugmaker to provide new medicines in Japan.
Amgen to make move into Japan, takes on Astellas as partner
* Sees first commercial launch of new drug in Japan in 2016
Basilea antifungal wins coveted U.S. orphan drug status
ZURICH, May 28 - Swiss biotech group Basilea has won coveted orphan drug status from U.S. health authorities for antifungal treatment isavuconazole, the company said on Tuesday.
Aveo says partner Astellas will not seek EU nod for kidney cancer drug
- Aveo Pharmaceuticals Inc said it was informed by its partner Astellas Pharma Inc that the Japanese company would not be seeking marketing approval for their experimental kidney cancer drug in Europe.
EU body backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
UPDATE 1-EU body backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
EU agency backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.
Astellas, GSK vie to make "high altitude" anemia pill
LONDON - Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
